The US Food and Drug Administration (FDA) has granted 510(k) clearance to DeepEcho’s foetal ultrasound analysis platform.

This decision allows the company to enhance prenatal care and expand access to this technology.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Utilising deep learning algorithms, the AI-powered solution automates real-time detection of foetal ultrasound views, aiding healthcare professionals by improving diagnostic accuracy and image evaluations.

The platform’s approach includes segmentation of structures for foetal biometry and amniotic fluid volume evaluation, offering a standardised analysis of foetal structures.

DeepEcho focuses on foetal ultrasound diagnostics, with a presence across three continents: Europe, Africa, and the US.

The solution was developed by the company’s team, comprising AI scientists, physicians, and medical imaging experts.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

DeepEcho chief medical officer and co-founder Dr Saad Slimani said: “This milestone underscores the power of combining AI with clinical expertise to solve some of the most critical problems in healthcare.

“With this FDA clearance, we are one step closer to making early, accurate prenatal diagnosis universally accessible and helping clinicians deliver better outcomes for families.”

DeepEcho noted that it is creating next-generation solutions that utilise AI to detect biomarkers.

These advancements aim to facilitate the early prediction of complex conditions like preeclampsia, a major cause of maternal and neonatal morbidity and death.

DeepEcho CEO and co-founder Youssef Bouyakhf said: “Our FDA clearance is a pivotal achievement, validating the rigour of our technology and the quality and safety of our product at DeepEcho.

“We are extremely excited about the potential behind our current solution and the very ambitious plans we have for DeepEcho with more advanced features that we will bring to market in the near future.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact